Study shows intramuscular delivery of Abilify improves acute agitation.

Publication: Drug Week

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2004 NewsRX

2004 JUN 11 - (NewsRx.com & NewsRx.net) -- Patients with schizophrenia, schizoaffective and schizophreniform disorders who received treatment with intramuscular (IM) administration of aripiprazole (Abilify) showed significant improvement in acute agitation as early as 45 minutes after dosing, according to a study presented at the 157th Annual Meeting of the American Psychiatric Association.

The study showed that treatment with IM aripiprazole resulted in significant symptom improvement in these patients, and was generally well tolerated, without excessive sedation or pain at the injection site.

"Patients experiencing acute agitation in schizophrenia are the most highly distressed and potentially disruptive group of patients," said David Daniel, MD, clinical professor of psychiatry at George Washington University. "This study shows that IM aripiprazole may help physicians...

Read the full article for free courtesy of your local library.